CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 123 enrolled
Drug / intervention
Potassium Nitrate +1 moreother
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03943095
NCT03943095Phase 2Completed

Randomized Controlled Examiner-Blind Phase II Exploratory Clinical Study to Characterize the Efficacy Profile of an Experimental Dual Active Combination Dentifrice for the Relief of Dentin Hypersensitivity, in Subjects With Clinically Diagnosed Dentin Hypersensitivity

GlaxoSmithKline·interventional·Posted May 9, 2019·Updated Sep 11, 2020

In Brief

A Phase 2 clinical trial evaluating Potassium Nitrate and Stannous Fluoride for Dentin Hypersensitivity and Dentin Sensitivity. Completed, enrolled 123 participants across 1 site.

Detailed Summary

This exploratory study will characterize the efficacy profile of an experimental dual active 5 percent (%) potassium nitrate/0.454% stannous fluoride dentifrice, compared to a single active 0.454% stannous fluoride desensitizing dentifrice, over an 8-week treatment period.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesCanada
Collaborators--

Timeline

Phase 2CompletedFinished
2020202120222023202420252026
First PostedMay 9, 2019
Enrollment StartMay 13, 2019
Primary CompletionAug 28, 2019
TodayJul 2, 2026
Enrollment to primary: 4 monthsPosted 7.1 years ago

Interventions

Potassium Nitrateother

The test dentifrice contains 5% w/w potassium nitrate.

Stannous Fluorideother

The test and control dentifrices contain 0.454% w/w stannous fluoride (1100 ppm fluoride).